Inhibition of alloxan-induced hyperglycaemia in mice by the pyridoindole stobadine.
Alloxan-induced hyperglycaemia was used as a model of free radical pathology to test the antioxidant activity of the pyridoindole drug, stobadine, in the intact mouse. Stobadine was injected intraperitoneally in a dose range 7.5-60 mg/kg prior to intravenous injection of alloxan (50 mg/kg), and blood glucose concentration 72 hr after alloxan administration was used as an index of alloxan toxicity. Stobadine efficiently suppressed the alloxan-induced hyperglycaemia in a dose-dependent manner. This protection against the diabetogenic effect of alloxan is consistent with the high efficacy of stobadine to scavenge hydroxyl radicals.